LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 134

Search options

  1. Article ; Online: GPCR drug discovery-moving beyond the orthosteric to the allosteric domain.

    Felder, Christian C

    Advances in pharmacology (San Diego, Calif.)

    2019  Volume 86, Page(s) 1–20

    Abstract: Allosteric modulation of G protein coupled receptors (GPCRs) is rapidly becoming a standard option for development of therapeutics headed to the clinic. Although GPCRs represent about 35% of marketed drugs, to date only two allosteric modulators have ... ...

    Abstract Allosteric modulation of G protein coupled receptors (GPCRs) is rapidly becoming a standard option for development of therapeutics headed to the clinic. Although GPCRs represent about 35% of marketed drugs, to date only two allosteric modulators have been approved for human use. However, many are now in early clinical development are can provide unique regulation of GPCRs including high selectivity along with physiologic temporal and spatial signaling. These molecules bind to a site that is distinct from the site where the endogenous agonist binds yet can provide robust modulation effects that span from the positive to the negative. Along with classical chemogenomic techniques, newer technology is being directly applied to their development including three dimensional biophysical structure-function analysis and in silico molecular dynamic simulations. The goal is to provide rationally designed molecules from well informed physical and in silico data to speed the discovery and development of the next generation therapeutics. In this chapter an example of the evolution of allosteric drug discovery targeting the muscarinic receptor family should serve to inform of progress in this exciting area of research and early drug development.
    MeSH term(s) Allosteric Regulation ; Allosteric Site ; Animals ; Drug Discovery ; Drug Evaluation, Preclinical ; Humans ; Ligands ; Receptors, G-Protein-Coupled/chemistry ; Receptors, G-Protein-Coupled/metabolism
    Chemical Substances Ligands ; Receptors, G-Protein-Coupled
    Language English
    Publishing date 2019-05-14
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1557-8925
    ISSN (online) 1557-8925
    DOI 10.1016/bs.apha.2019.04.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.

    Yohn, Samantha E / Weiden, Peter J / Felder, Christian C / Stahl, Stephen M

    Trends in pharmacological sciences

    2022  Volume 43, Issue 12, Page(s) 1098–1112

    Abstract: Modern interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia began in the 1990s when xanomeline, an ... ...

    Abstract Modern interest in muscarinic acetylcholine receptor (mAChR) activators for schizophrenia began in the 1990s when xanomeline, an M
    MeSH term(s) Humans ; Muscarinic Agonists/pharmacology ; Muscarinic Agonists/therapeutic use ; Receptors, Muscarinic ; Schizophrenia/drug therapy ; Psychotic Disorders/drug therapy ; Acetylcholine ; Receptor, Muscarinic M1/agonists
    Chemical Substances Muscarinic Agonists ; Receptors, Muscarinic ; Acetylcholine (N9YNS0M02X) ; Receptor, Muscarinic M1
    Language English
    Publishing date 2022-10-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 282846-7
    ISSN 1873-3735 ; 0165-6147
    ISSN (online) 1873-3735
    ISSN 0165-6147
    DOI 10.1016/j.tips.2022.09.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: An assessment of the informative value of data sharing statements in clinical trial registries.

    Ohmann, Christian / Panagiotopoulou, Maria / Canham, Steve / Felder, Gerd / Verde, Pablo Emilio

    BMC medical research methodology

    2024  Volume 24, Issue 1, Page(s) 61

    Abstract: Background: The provision of data sharing statements (DSS) for clinical trials has been made mandatory by different stakeholders. DSS are a device to clarify whether there is intention to share individual participant data (IPD). What is missing is a ... ...

    Abstract Background: The provision of data sharing statements (DSS) for clinical trials has been made mandatory by different stakeholders. DSS are a device to clarify whether there is intention to share individual participant data (IPD). What is missing is a detailed assessment of whether DSS are providing clear and understandable information about the conditions for data sharing of IPD for secondary use.
    Methods: A random sample of 200 COVID-19 clinical trials with explicit DSS was drawn from the ECRIN clinical research metadata repository. The DSS were assessed and classified, by two experienced experts and one assessor with less experience in data sharing (DS), into different categories (unclear, no sharing, no plans, yes but vague, yes on request, yes with specified storage location, yes but with complex conditions).
    Results: Between the two experts the agreement was moderate to substantial (kappa=0.62, 95% CI [0.55, 0.70]). Agreement considerably decreased when these experts were compared with a third person who was less experienced and trained in data sharing ("assessor") (kappa=0.33, 95% CI [0.25, 0.41]; 0.35, 95% CI [0.27, 0.43]). Between the two experts and under supervision of an independent moderator, a consensus was achieved for those cases, where both experts had disagreed, and the result was used as "gold standard" for further analysis. At least some degree of willingness of DS (data sharing) was expressed in 63.5% (127/200) cases. Of these cases, around one quarter (31/127) were vague statements of support for data sharing but without useful detail. In around half of the cases (60/127) it was stated that IPD could be obtained by request. Only in in slightly more than 10% of the cases (15/127) it was stated that the IPD would be transferred to a specific data repository. In the remaining cases (21/127), a more complex regime was described or referenced, which could not be allocated to one of the three previous groups. As a result of the consensus meetings, the classification system was updated.
    Conclusion: The study showed that the current DSS that imply possible data sharing are often not easy to interpret, even by relatively experienced staff. Machine based interpretation, which would be necessary for any practical application, is currently not possible. Machine learning and / or natural language processing techniques might improve machine actionability, but would represent a very substantial investment of research effort. The cheaper and easier option would be for data providers, data requestors, funders and platforms to adopt a clearer, more structured and more standardised approach to specifying, providing and collecting DSS.
    Trial registration: The protocol for the study was pre-registered on ZENODO ( https://zenodo.org/record/7064624#.Y4DIAHbMJD8 ).
    MeSH term(s) Humans ; Research Design ; Information Dissemination/methods ; Consensus ; Registries
    Language English
    Publishing date 2024-03-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2041362-2
    ISSN 1471-2288 ; 1471-2288
    ISSN (online) 1471-2288
    ISSN 1471-2288
    DOI 10.1186/s12874-024-02168-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.

    Paul, Steven M / Yohn, Samantha E / Popiolek, Michael / Miller, Andrew C / Felder, Christian C

    The American journal of psychiatry

    2022  Volume 179, Issue 9, Page(s) 611–627

    Abstract: Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. ...

    Abstract Schizophrenia remains a challenging disease to treat effectively with current antipsychotic medications due to their limited efficacy across the entire spectrum of core symptoms as well as their often burdensome side-effect profiles and poor tolerability. An unmet need remains for novel, mechanistically unique, and better tolerated therapeutic agents for treating schizophrenia, especially those that treat not only positive symptoms but also the negative and cognitive symptoms of the disease. Almost 25 years ago, the muscarinic acetylcholine receptor (mAChR) agonist xanomeline was reported to reduce psychotic symptoms and improve cognition in patients with Alzheimer's disease. The antipsychotic and procognitive properties of xanomeline were subsequently confirmed in a small study of acutely psychotic patients with chronic schizophrenia. These unexpected clinical findings have prompted considerable efforts across academia and industry to target mAChRs as a new approach to potentially treat schizophrenia and other psychotic disorders. The authors discuss recent advances in mAChR biology and pharmacology and the current understanding of the relative roles of the various mAChR subtypes, their downstream cellular effectors, and key neural circuits mediating the reduction in the core symptoms of schizophrenia in patients treated with xanomeline. They also provide an update on the status of novel mAChR agonists currently in development for potential treatment of schizophrenia and other neuropsychiatric disorders.
    MeSH term(s) Antipsychotic Agents/pharmacology ; Antipsychotic Agents/therapeutic use ; Humans ; Muscarinic Agonists/pharmacology ; Muscarinic Agonists/therapeutic use ; Psychotic Disorders/drug therapy ; Receptors, Muscarinic ; Schizophrenia/drug therapy
    Chemical Substances Antipsychotic Agents ; Muscarinic Agonists ; Receptors, Muscarinic
    Language English
    Publishing date 2022-06-27
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 280045-7
    ISSN 1535-7228 ; 0002-953X
    ISSN (online) 1535-7228
    ISSN 0002-953X
    DOI 10.1176/appi.ajp.21101083
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Author Correction: Structural basis of efficacy-driven ligand selectivity at GPCRs.

    Powers, Alexander S / Pham, Vi / Burger, Wessel A C / Thompson, Geoff / Laloudakis, Yianni / Barnes, Nicholas W / Sexton, Patrick M / Paul, Steven M / Christopoulos, Arthur / Thal, David M / Felder, Christian C / Valant, Celine / Dror, Ron O

    Nature chemical biology

    2023  Volume 19, Issue 4, Page(s) 529

    Language English
    Publishing date 2023-03-05
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 2202962-X
    ISSN 1552-4469 ; 1552-4450
    ISSN (online) 1552-4469
    ISSN 1552-4450
    DOI 10.1038/s41589-023-01297-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book ; Online: The impact of external innovation on new drug approvals

    Liu, Xiong / Thomas, Craig E. / Felder, Christian C.

    A retrospective analysis

    2021  

    Abstract: Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still ... ...

    Abstract Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still required in order to better understand how to best leverage the innovation ecosystem. We analyzed the pre-approval publication histories for FDA-approved new molecular entities (NMEs) and new biologic entities (NBEs) launched by 13 top research pharma companies during the last decade (2006-2016). We found that academic institutions contributed the majority of pre-approval publications and that publication subject matter is closely aligned with the strengths of the respective innovator. We found this to also be true for candidate drugs terminated in Phase 3, but the volume of literature on these molecules is substantially less than for approved drugs. This may suggest that approved drugs are often associated with a more robust dataset provided by a large number of institutes. Collectively, the results of our analysis support the hypothesis that a collaborative research innovation environment spanning across academia, industry and government is highly conducive to successful drug approvals.
    Keywords Computer Science - Computation and Language ; Computer Science - Computers and Society ; Quantitative Biology - Quantitative Methods
    Subject code 001
    Publishing date 2021-02-01
    Publishing country us
    Document type Book ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: The impact of external innovation on new drug approvals: A retrospective analysis.

    Liu, Xiong / Thomas, Craig E / Felder, Christian C

    International journal of pharmaceutics

    2019  Volume 563, Page(s) 273–281

    Abstract: Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still ... ...

    Abstract Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still required in order to better understand how to best leverage the innovation ecosystem. We analyzed the pre-approval publication histories for FDA-approved new molecular entities (NMEs) and new biologic entities (NBEs) launched by 13 top research pharma companies during the last decade (2006-2016). We found that academic institutions contributed the majority of pre-approval publications and that publication subject matter is closely aligned with the strengths of the respective innovator. We found this to also be true for candidate drugs terminated in Phase 3, but the volume of literature on these molecules is substantially less than for approved drugs. This may suggest that approved drugs are often associated with a more robust dataset provided by a large number of institutes. Collectively, the results of our analysis support the hypothesis that a collaborative research innovation environment spanning across academia, industry and government is highly conducive to successful drug approvals.
    MeSH term(s) Biological Products ; Drug Approval/statistics & numerical data ; Drug Industry/statistics & numerical data ; Public-Private Sector Partnerships ; United States ; United States Food and Drug Administration ; Universities/statistics & numerical data
    Chemical Substances Biological Products
    Language English
    Publishing date 2019-01-18
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 428962-6
    ISSN 1873-3476 ; 0378-5173
    ISSN (online) 1873-3476
    ISSN 0378-5173
    DOI 10.1016/j.ijpharm.2018.12.093
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Changing the tide in vitamin D testing: An 8-year review of a demand management approach.

    Cadamuro, Janne / Huber-Schönauer, Ursula / Mrazek, Cornelia / Hehenwarter, Lukas / Kipman, Ulrike / Felder, Thomas K / Pirich, Christian

    Biochemia medica

    2024  Volume 34, Issue 1, Page(s) 10401

    MeSH term(s) Humans ; Clinical Laboratory Techniques ; Specimen Handling ; Vitamin D
    Chemical Substances Vitamin D (1406-16-2)
    Language English
    Publishing date 2024-02-06
    Publishing country Croatia
    Document type Journal Article
    ZDB-ID 1208725-7
    ISSN 1846-7482 ; 1330-0962
    ISSN (online) 1846-7482
    ISSN 1330-0962
    DOI 10.11613/BM.2024.010401
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: AMIC for Focal Osteochondral Defect of the Talar Shoulder.

    Götze, Christian / Nieder, Christian / Felder, Hanna / Migliorini, Filippo

    Life (Basel, Switzerland)

    2020  Volume 10, Issue 12

    Abstract: Background: The management of a focal osteochondral lesion of the talus (OLT) is challenging. Evidence concerning the role of the autologous matrix-induced chondrogenesis (AMIC) procedure in patients with focal OLT is promising. The purpose of the ... ...

    Abstract Background: The management of a focal osteochondral lesion of the talus (OLT) is challenging. Evidence concerning the role of the autologous matrix-induced chondrogenesis (AMIC) procedure in patients with focal OLT is promising. The purpose of the present study was to investigate clinical outcomes and radiographic findings of the AMIC technique for focal unipolar OLT.
    Material and methods: The present study was performed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Twenty-four patients who underwent AMIC for focal OLT were prospectively recruited at our institution. All the surgeries were performed by two experienced surgeons through malleolar osteotomy and autologous cancellous bone grafting. The outcomes of interest were the American orthopedic foot and ankle score (AOFAS), the foot-function index (FFI), and the magnetic resonance observation of cartilage repair tissue (MOCART). Surgical duration, hospitalization length, and complications were also collected.
    Results: 24 patients were included in the present study. The mean follow-up was 25.17 ± 13.1 months. The mean age of the patients at surgery was 46.75 ± 15.2 years, the mean BMI 26.92 ± 5.7 kg/m
    Conclusion: The AMIC procedure for focal osteochondral defects of the talar shoulder is feasible and reliable at midterm follow-up.
    Language English
    Publishing date 2020-12-05
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662250-6
    ISSN 2075-1729
    ISSN 2075-1729
    DOI 10.3390/life10120328
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Structural basis of efficacy-driven ligand selectivity at GPCRs.

    Powers, Alexander S / Pham, Vi / Burger, Wessel A C / Thompson, Geoff / Laloudakis, Yianni / Barnes, Nicholas W / Sexton, Patrick M / Paul, Steven M / Christopoulos, Arthur / Thal, David M / Felder, Christian C / Valant, Celine / Dror, Ron O

    Nature chemical biology

    2023  Volume 19, Issue 7, Page(s) 805–814

    Abstract: A drug's selectivity for target receptors is essential to its therapeutic utility, but achieving selectivity between similar receptors is challenging. The serendipitous discovery of ligands that stimulate target receptors more strongly than closely ... ...

    Abstract A drug's selectivity for target receptors is essential to its therapeutic utility, but achieving selectivity between similar receptors is challenging. The serendipitous discovery of ligands that stimulate target receptors more strongly than closely related receptors, despite binding with similar affinities, suggests a solution. The molecular mechanism of such 'efficacy-driven selectivity' has remained unclear, however, hindering design of such ligands. Here, using atomic-level simulations, we reveal the structural basis for the efficacy-driven selectivity of a long-studied clinical drug candidate, xanomeline, between closely related muscarinic acetylcholine receptors (mAChRs). Xanomeline's binding mode is similar across mAChRs in their inactive states but differs between mAChRs in their active states, with divergent effects on active-state stability. We validate this mechanism experimentally and use it to design ligands with altered efficacy-driven selectivity. Our results suggest strategies for the rational design of ligands that achieve efficacy-driven selectivity for many pharmaceutically important G-protein-coupled receptors.
    MeSH term(s) Ligands ; Receptors, Muscarinic/chemistry ; Receptors, Muscarinic/metabolism ; Pyridines ; Thiadiazoles/chemistry ; Receptors, G-Protein-Coupled/chemistry
    Chemical Substances Ligands ; xanomeline (9ORI6L73CJ) ; Receptors, Muscarinic ; Pyridines ; Thiadiazoles ; Receptors, G-Protein-Coupled
    Language English
    Publishing date 2023-02-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2202962-X
    ISSN 1552-4469 ; 1552-4450
    ISSN (online) 1552-4469
    ISSN 1552-4450
    DOI 10.1038/s41589-022-01247-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top